China Resources Boya Bio-pharmaceutical Group Co.,Ltd

XSEC:300294 Stock Report

Market Cap: CN¥15.6b

China Resources Boya Bio-pharmaceutical GroupLtd Past Earnings Performance

Past criteria checks 0/6

China Resources Boya Bio-pharmaceutical GroupLtd's earnings have been declining at an average annual rate of -5.8%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been declining at an average rate of 3.9% per year. China Resources Boya Bio-pharmaceutical GroupLtd's return on equity is 2.5%, and it has net margins of 10.9%.

Key information

-5.8%

Earnings growth rate

-10.4%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate-3.9%
Return on equity2.5%
Net Margin10.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How China Resources Boya Bio-pharmaceutical GroupLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XSEC:300294 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,70718656767
30 Jun 242,00722863260
31 Mar 242,29521971477
31 Dec 232,65223777768
30 Sep 232,86647885862
30 Jun 232,90147990665
31 Mar 232,91049991353
31 Dec 222,75943292650
30 Sep 222,72243995543
30 Jun 222,75442697138
31 Mar 222,68134796258
31 Dec 212,65134597059
30 Sep 212,66736099293
30 Jun 212,5862971,01897
31 Mar 212,5282651,03379
31 Dec 202,5132601,03089
30 Sep 202,6643321,05895
30 Jun 202,7553741,06099
31 Mar 202,8674331,10499
31 Dec 192,9094261,14693
30 Sep 192,8675011,10564
30 Jun 192,7354911,04257
31 Mar 192,60948698749
31 Dec 182,38846990245
30 Sep 182,30741985338
30 Jun 182,01239071952
31 Mar 181,73236263142
31 Dec 171,39035751335
30 Sep 171,13231636723
30 Jun 171,0853243470
31 Mar 179943012790
31 Dec 169472722700
30 Sep 168392272420
30 Jun 167201872170
31 Mar 166151451960
31 Dec 155431521780
30 Sep 154981381640
30 Jun 154721301580
31 Mar 154521301490
31 Dec 144381041410
30 Sep 14366961070
30 Jun 1432189910
31 Mar 1427885730
31 Dec 1324582590

Quality Earnings: 300294 has a large one-off loss of CN¥325.5M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 300294's current net profit margins (10.9%) are lower than last year (16.7%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300294's earnings have declined by 5.8% per year over the past 5 years.

Accelerating Growth: 300294's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 300294 had negative earnings growth (-61.1%) over the past year, making it difficult to compare to the Biotechs industry average (1.3%).


Return on Equity

High ROE: 300294's Return on Equity (2.5%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 01:01
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

China Resources Boya Bio-pharmaceutical Group Co.,Ltd is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shuchang LiuChangjiang Securities Co. LTD.
Fang QuanChina International Capital Corporation Limited
Bing ZhaoChina Renaissance Securities